Xbrane Biopharma AB (OSTO:XBRANE) Cyclically Adjusted Book per Share: kr190.04 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:XBRANE Xbrane Biopharma AB OSTO:XBRANE
71 GF Score
Price kr9.18
GF Value kr6.00
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB Cyclically Adjusted Book per Share?

Xbrane Biopharma AB OSTO:XBRANE -1.92% 71 Cyclically Adjusted Book per Share is kr190.04 as of Jun. 2026. GuruFocus rates OSTO:XBRANE with a GF Score™ of 71/100 and a GF Value™ of kr6.00 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Xbrane Biopharma AB's adjusted book value per share for the three months ended in Jun. 2026 was kr26.151. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr190.04 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Xbrane Biopharma AB's average Cyclically Adjusted Book Growth Rate was -14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-27), Xbrane Biopharma AB's current stock price is kr9.18. Xbrane Biopharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was kr190.04. Xbrane Biopharma AB's Cyclically Adjusted PB Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Xbrane Biopharma AB was 0.16. The lowest was 0.03. And the median was 0.09.


Xbrane Biopharma AB  (OSTO:XBRANE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Xbrane Biopharma AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=9.18/190.04
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Xbrane Biopharma AB was 0.16. The lowest was 0.03. And the median was 0.09.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Xbrane Biopharma AB Cyclically Adjusted Book per Share Related Terms


Xbrane Biopharma AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Xbrane Biopharma AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB Cyclically Adjusted Book per Share Chart

Xbrane Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 230.16 211.90

Xbrane Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.05 210.17 211.90 200.06 190.04

OSTO:XBRANE vs VRTX, REGN, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Cyclically Adjusted PB Ratio falls into.


OSTO:XBRANE
71GF Score
Xbrane Biopharma AB OSTO:XBRANE
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xbrane Biopharma AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xbrane Biopharma AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=26.151/134.6100*134.6100
=26.151

Current CPI (Jun. 2026) = 134.6100.

Xbrane Biopharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 343.032 101.138 456.562
201612 321.754 102.022 424.531
201703 273.333 102.022 360.643
201706 238.851 102.752 312.905
201709 238.278 103.279 310.563
201712 199.560 103.793 258.812
201803 188.781 103.962 244.434
201806 118.036 104.875 151.503
201809 243.168 105.679 309.739
201812 176.369 105.912 224.159
201903 221.750 105.886 281.904
201906 321.085 106.742 404.915
201909 222.168 107.214 278.938
201912 146.463 107.766 182.946
202003 128.216 106.563 161.962
202006 140.593 107.498 176.052
202009 99.174 107.635 124.028
202012 164.459 108.296 204.420
202103 132.974 108.360 165.187
202106 95.497 108.928 118.013
202109 261.704 110.338 319.273
202112 244.336 112.486 292.393
202203 224.250 114.825 262.889
202206 206.163 118.384 234.421
202209 184.193 122.296 202.739
202212 218.902 126.365 233.184
202303 189.286 127.042 200.562
202306 193.981 129.407 201.781
202309 157.892 130.224 163.210
202312 81.433 131.912 83.099
202403 32.210 132.205 32.796
202406 24.889 132.716 25.244
202409 21.261 132.304 21.632
202412 17.043 132.987 17.251
202503 17.643 132.825 17.880
202506 31.399 133.699 31.613
202509 28.491 133.480 28.732
202512 27.210 133.390 27.459
202603 26.700 133.560 26.910
202606 26.151 134.610 26.151

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr190.04 mean?
Xbrane Biopharma AB (OSTO:XBRANE) has a Cyclically Adjusted Book per Share of kr190.04 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's Cyclically Adjusted Book per Share too high?
Xbrane Biopharma AB's current Cyclically Adjusted Book per Share is kr190.04. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Xbrane Biopharma AB's Cyclically Adjusted Book per Share of kr190.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current Cyclically Adjusted Book per Share is kr190.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Xbrane Biopharma AB (OSTO:XBRANE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.00, compared to a current price of kr9.18 — trading 53% above its estimated fair value. The current Cyclically Adjusted Book per Share is kr190.04. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Xbrane Biopharma AB (OSTO:XBRANE), the current Cyclically Adjusted Book per Share is kr190.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (OSTO:XBRANE) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of kr9.18 is trading 53% above its estimated GF Value™ of kr6.00. GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:XBRANE:

  • Cyclically Adjusted Book per Share: kr190.04
  • GF Value™: kr6.00 vs. price of kr9.18 (53% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the OSTO:XBRANE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xbrane Biopharma AB Business Description

Other Exchanges 7XB0:Germany
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for OSTO:XBRANE

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.18
Price
kr6.00
GF Value